PMC:7443692 / 289-502 JSONTXT

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T5","span":{"begin":201,"end":206},"obj":"Species"}],"attributes":[{"id":"A5","pred":"ncbi_taxonomy_id","subj":"T5","obj":"NCBItxid:9606"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"ll entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. "}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T4","span":{"begin":10,"end":212},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ll entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. "}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T104","span":{"begin":207,"end":211},"obj":"Protein"}],"attributes":[{"id":"A104","pred":"uniprot_id","subj":"T104","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"}],"text":"ll entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. "}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T5","span":{"begin":73,"end":77},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"}],"text":"ll entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. "}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T1","span":{"begin":109,"end":122},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"ll entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. "}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T1","span":{"begin":109,"end":122},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"ll entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. "}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T11","span":{"begin":41,"end":56},"obj":"CHEBI:17089;CHEBI:17089"},{"id":"T12","span":{"begin":162,"end":171},"obj":"CHEBI:60816;CHEBI:60816"},{"id":"T13","span":{"begin":201,"end":206},"obj":"SP_6;NCBITaxon:9606;PG_10"},{"id":"T14","span":{"begin":207,"end":211},"obj":"PG_10;PR:000003622"}],"text":"ll entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. "}